Oxford Asset Management’s Gyre Therapeutics GYRE Stock Holding History

Oxford Asset Management’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-6,250	Closed	-$370K	–	1784
2018 Q4	$370K	Buy	6,250 +1,989	+47%	+$147K	0.01%	1318
2018 Q3	$342K	Buy	+4,261	New	+$338K	0.01%	1459
2015 Q3	–	Sell	-17	Closed	-$37K	–	666
2015 Q2	$37K	Sell	17 -20	-54%	-$40.1K	﹤0.01%	638
2015 Q1	$87K	Sell	37 -4	-10%	-$8.26K	﹤0.01%	635
2014 Q4	$84K	Buy	+41	New	+$79K	﹤0.01%	654
2014 Q2	–	Sell	-14	Closed	-$54K	–	731
2014 Q1	$54K	Buy	+14	New	+$51.8K	﹤0.01%	631

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Oxford Asset Management's GYRE Position: Q1 2019 in Review

Oxford Asset Management sold out of Gyre Therapeutics (GYRE) in Q1 2019, closing a stake of 6,250 shares — an estimated $370K sold.

Oxford Asset Management first reported a position in GYRE in Q1 2014 and held it in 6 quarters. The position peaked at $370K in Q4 2018. 63 funds tracked by Wall St. Rank hold GYRE as of Q1 2019.

Oxford Asset Management reported no remaining Gyre Therapeutics position as of Q1 2019 after selling out during the quarter.
Oxford Asset Management sold 6,250 Gyre Therapeutics shares in Q1 2019, an estimated $370K.
Oxford Asset Management first reported a position in Gyre Therapeutics in Q1 2014 and held it in 6 quarters.
Oxford Asset Management's Gyre Therapeutics position peaked at $370K in Q4 2018.
63 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.